Ash Alizadeh, MD/PhD 🇺🇸

Excited to share our new study of risk of T-cell #lymphomas after #CAR therapy. 1/15 🧵 nejm.org/doi/full/10.10…

Extending access for life-saving CAR-T therapies! fda.gov/vaccines-blood…

I couldn’t resist highlighting the beautiful first page of our recent @BCD_AACR @AACR article, which unveils the two distinct #Epitypes #DNA #Methylation profiles that characterize #Burkitt #lymphoma aacrjournals.org/bloodcancerdis…

Excited to share this new publication in @Haematologica from our group @fredhutch investigating the impact of extramedullary disease on CAR T-cell-associated toxicities in patients with myeloma. Work brilliantly led by Dr. @AJPortuguese! 🔗 to manuscript: doi.org/10.3324/haemat……

Grazie Franco and the whole Lugano/Bellinzona team for yet another great #ICML. See you in 2027!

$LYEL - Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma - stocktitan.net/news/LYEL/lyel…

The big debate 3: Smith vs Nowakowski: Is Pola-R-CHP the new standard for all DLBCL? No.

Congrats @GregNowakowski ! It was a clear win at 80:20, wonderful presentation! You nailed it!

🚨🚨We are pleased to publish the next output via the HoLISTIC consortium (Hodgkin Lymphoma International STudy for Individual Care: hodgkinconsortium.com): The E-HIPI (Early-Stage Hodgkin International Prognostic Index) prediction model for early-stage Hodgkin lymphoma. 1/9🧵

Data from the Shipp lab @DanaFarber support that the benefit of polatuzumab in 1L DLBCL is isolated to a subgroup of patients with C5 DLBCL, a subset of the ABC group #18ICML #lymsm

There's been a sharp fall in the number of videos recorded by Iranians and posted to social media documenting Israeli strikes around the country today due to a near total internet shutdown being imposed by the authorities. The nationwide outage has made it difficult for…

ICYMI: tafa-R^2 approved by FDA for R/R FL with at least one prior line of systemic therapy. #18ICML #lymsm fda.gov/drugs/resource…

Here’s an updated version of our table - in addition the POLARIX Asian extension cohort found the same thing, plus our observational cohort of >700 patients presented at ASH. So 11/12 studies (7/8 trials, POLARGO being the first exception) show the same trend #18ICML

Is pola-Gem Ox any better than pola alone? It causes more neuropathy. Let’s hope the future sees us moving beyond R-GemOx as a (poor) comparator arm. #18ICML

#18ICML #lymsm

BREAKING: Top gene therapy regulator forced out at FDA Nicole Verdun and her deputy placed on leave. statnews.com/2025/06/18/top… via @Jasonmmast and me.

We are deeply saddened by the passing of Dr. Atul Butte, a visionary scientist, educator and leader whose work reshaped biomedical research and health care. We extend our heartfelt condolences to Dr. Butte’s family, colleagues, trainees and collaborators. ucsfh.org/4n25xVH

Celebration of the life of Atul Butte. Join colleagues from three universities to celebrate him at 10 am PST on Saturday.

My husband, the incredible Lymphoma specialist @Lymphoma_Doc - has been a tireless advocate for our patients and @ASCO - check out his master class on how to advocate as a physician....Definitely required viewing!!! #ASCO25 #advocacy shorturl.at/zMxCy

CONGRESS | #ASCO25 | PRESENTATION Steven Wang @wngsteven @amsterdamumc presents results from a prospective validation of end-of-treatment ctDNA-MRD by PhasED-Seq in patients with DLBCL treated with 1L R-CHOP or DA-EPOCH-R in a national cohort (N = 160). MRD+ status significantly…

At #ASCO25, Steven Wang shows that EOT ctDNA-MRD is a powerful prognostic marker in 1L DLBCL. 📌 2-yr PFS: MRD–: 90% vs MRD+: 23% 📌 2-yr OS: MRD–: 97% vs MRD+: 46% ➡️ Prog value independent of PET/CT and IPI ➡️ Integration into routine response assessment is strongly supported.